REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search

CAR T-cell Therapy for Multiple Myeloma at Sheba Medical Center

Previously offered only to patients with leukemia or lymphoma, CAR T-cell therapy is now available at Sheba as a treatment for multiple myeloma.

CAR T-cell Therapy

How Does CAR T-cell Therapy Work?

CAR T-cell therapy is a revolutionary blood cancer treatment that helps the body combat tumors using its own T-cells. The therapy involves collecting the patient’s blood, separating T-cells, and genetically engineering them to produce chimeric antigen receptors (CARs). These allow the T-cells to recognize cancerous tissue, targeting and destroying it. After they are modified, these T-cells are multiplied in a laboratory and then reintroduced to the patient’s body.

CAR T-cell therapy is a cutting-edge, highly specialized procedure, and is available at a limited number of cancer centers around the world.

A New Treatment for Multiple Myeloma at Sheba

Until recently, Sheba offered CAR T-cell therapy for patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma.

Following recent FDA approval, we are pleased to announce that CAR T-cell therapy is now available for the treatment of multiple myeloma (MM) patients.

Commenting on the addition of CAR T-cell therapy to the multiple myeloma therapeutic arsenal, Director of the Multiple Myeloma Unit at Sheba, Dr. Hila Magen, explained: “We are talking about an advanced immunotherapy that ‘re-educates’ the patient’s immune system to fight cancerous myeloma cells. It is truly an incredible breakthrough that opens the door for new multiple myeloma therapeutic approaches.”

CAR T-cell Therapy

Why Chose Sheba for CAR T-cell Therapy

Unparalleled Experience

Sheba’s extensive experience with CAR T-cell therapy speaks louder than words. Led by Prof. Arnon Nagler, President of the Hemato-Oncology Center and a world-renowned specialist in the field, we have provided over 220 patients with CAR-T therapy, including about 60 children.

Efficient, Comfortable, and Patient-Centric Experience

CAR-T therapy at Sheba is all-inclusive. That means all stages of the process are done on campus, including blood harvesting, genetic engineering of the cells, T-cell injections, and patient observation. The patient experience is therefore as convenient and comfortable as possible.

Fast Availability of CARs

CARs are more readily available at Sheba because the cells are engineered at an on-site laboratory, a process that only takes about 10 days to complete. In contrast, other medical centers use commercial CARs that must be shipped overseas for engineering, so the entire process, from lymphocyte collection to delivery, can take weeks or even months. The extra wait-time not only gives the disease time to progress, but also reduces the chances of a positive patient response to the CARs.

World-renowned Experts

The physicians at Sheba are some of the most experienced in the world in the field of CAR-T therapy. Prof. Nagler, a renowned expert on the topic, is one of the three board members of the organizing committee for the largest European conference held annually on CAR T-cell therapy.

CANCER CENTER

Request a consultation

Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.

We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.

Request a consultation and a Sheba Case Manager will contact you shortly: